{"entity":{"id":"nct01886105","kind":"trial","name":"Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma","aka":[],"tldr":"A phase 2 trial of Samarium-153 lexidronam in Osteosarcoma, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, recorded as terminated on the registry.","summary":"Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma is a phase 2 interventional study registered as NCT01886105 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with 4 participants recorded, started 2013-08-19 and due to reach its primary completion in 2015-12-11. Interventions recorded: Sm-EDTMP, Autologous Stem Cell Infusion, External Beam Radiotherapy. Conditions recorded: Metastatic Osteosarcoma.\n\nLinked to the drug Samarium-153 lexidronam because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01886105","url":"https://clinicaltrials.gov/study/NCT01886105"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["samarium-153-lexidronam"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01886105","phase":"2","setting":"Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","enrolled":4,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01886105/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"drug":[{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/"}]}}